{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-038630","form_type":"8-K","ticker":"VIR","cik":"0001706431","company_name":"Vir Biotechnology, Inc.","filed_at":"2026-05-28T13:01:18+00:00","discovered_at":"2026-05-28T13:02:00.268108+00:00","generated_at":"2026-05-28T13:04:22.570135+00:00","sec_items":["5.02","5.07"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vir Biotechnology director Saira Ramasastry resigns; board shrinks to 7; annual meeting elects directors","bullets":["Saira Ramasastry steps down from board and audit committee effective May 26, 2026, due to business conflict; no disagreement with company.","Robert More appointed Audit Committee Chair; board size reduced from 8 to 7 upon Ramasastry's departure.","At May 26 annual meeting, Class I directors Robert More, Janet Napolitano, and Elliott Sigal elected; Napolitano received 67.2M for, 54.5M withheld.","Advisory vote on named executive officer compensation approved: 108.5M for, 11.9M against, 1.4M abstain.","Ratification of Ernst & Young as independent auditor for FY2026 approved: 137.0M for, 0.15M against."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-038630","json":"https://secwatch.observer/filing/0001628280-26-038630.json","markdown":"https://secwatch.observer/filing/0001628280-26-038630.md","text":"https://secwatch.observer/filing/0001628280-26-038630.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038630/0001628280-26-038630-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038630/vir-20260525.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T13:04:22.570135+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"305e0fce20","claim":"Saira Ramasastry departed as Director at Vir Biotechnology, Inc..","evidence_excerpt":"On May 25, 2026, Saira Ramasastry, M.S., M.Phil., a member of the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) and Chair of the Company’s Audit Committee (the Audit Committee), informed the Company that, due to a business conflict, she will be stepping down from her role as a member of the Board and the Audit Committee, effective May 26, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038630/0001628280-26-038630-index.htm","confidence":1.0}],"comparable_filings":[{"accession":"0001213900-26-063506","ticker":"GPOR","company_name":"GULFPORT ENERGY CORP","filed_at":"2026-06-01T20:10:03+00:00","headline":"Gulfport Energy appoints Domenic Dell'Osso to Board; CEO role effective May 28, 2026","event_type":"leadership","sec_items":["5.02","5.07"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 5.07","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063506","json":"https://secwatch.observer/filing/0001213900-26-063506.json","markdown":"https://secwatch.observer/filing/0001213900-26-063506.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/874499/000121390026063506/0001213900-26-063506-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874499/000121390026063506/ea0292798-8k_gulfport.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 25, 2026, Saira Ramasastry, M.S., M.Phil., a member of the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) and Chair of the Company’s Audit Committee (the Audit Committee), informed the Company that, due to a business conflict, she will be stepping down from her role as a member of the Board and the Audit Committee, effective May 26, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038630/0001628280-26-038630-index.htm","comparable_excerpt":"On May 28, 2026, the Board voted to increase the size of the Board to seven members and appointed Domenic J. Dell’Osso, Jr. to serve as a member of the Board until the 2027 Annual Meeting of Stockholders or until his successor is duly elected and qualified.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/874499/000121390026063506/0001213900-26-063506-index.htm"}},{"accession":"0000927089-26-000101","ticker":"MGNO","company_name":"Magnolia Bancorp, Inc.","filed_at":"2026-06-01T18:15:36+00:00","headline":"Magnolia Bancorp names Robert Kimbro President/CEO; Hurley becomes Executive Chair","event_type":"leadership","sec_items":["5.02","5.07","7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 5.07","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000927089-26-000101","json":"https://secwatch.observer/filing/0000927089-26-000101.json","markdown":"https://secwatch.observer/filing/0000927089-26-000101.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2033615/000092708926000101/0000927089-26-000101-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2033615/000092708926000101/mban20260520_8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 25, 2026, Saira Ramasastry, M.S., M.Phil., a member of the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) and Chair of the Company’s Audit Committee (the Audit Committee), informed the Company that, due to a business conflict, she will be stepping down from her role as a member of the Board and the Audit Committee, effective May 26, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038630/0001628280-26-038630-index.htm","comparable_excerpt":"On May 28, 2026, both the Company and the Association appointed Robert W. Kimbro as their President and Chief Executive Officer effective as of June 1, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2033615/000092708926000101/0000927089-26-000101-index.htm"}},{"accession":"0001437749-26-018719","ticker":"BELFA","company_name":"BEL FUSE INC /NJ","filed_at":"2026-05-28T18:24:48+00:00","headline":"Bel Fuse names Kenneth Lai as SVP ITDS; annual meeting approves 2026 equity plan","event_type":"leadership","sec_items":["5.02","5.07","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 5.07","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-018719","json":"https://secwatch.observer/filing/0001437749-26-018719.json","markdown":"https://secwatch.observer/filing/0001437749-26-018719.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/729580/000143774926018719/0001437749-26-018719-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/729580/000143774926018719/belfa20260526_8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 25, 2026, Saira Ramasastry, M.S., M.Phil., a member of the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) and Chair of the Company’s Audit Committee (the Audit Committee), informed the Company that, due to a business conflict, she will be stepping down from her role as a member of the Board and the Audit Committee, effective May 26, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038630/0001628280-26-038630-index.htm","comparable_excerpt":"on May 22, 2026, the Company determined to name Kenneth Lai as Senior Vice President ITDS, effective late second quarter or early third quarter of 2026. In this role, Mr. Lai’s responsibilities expand to include the Company’s India and private label operations, in addition to China and other Asia locations. As a result of this change in responsibilities, Mr. Lai is no longer determined to be an “executive officer” or “officer” of the Company as defined in Rules 3b-7 and 16a-1(f) under the Securities Exchange Act of 1934, as amended, respectively.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/729580/000143774926018719/0001437749-26-018719-index.htm"}},{"accession":"0001628280-26-038504","ticker":"HNST","company_name":"Honest Company, Inc.","filed_at":"2026-05-27T20:35:39+00:00","headline":"The Honest Company promotes Curtiss Bruce to Chief Financial & Operating Officer and announces annual meeting results","event_type":"leadership","sec_items":["5.02","5.07"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 5.07","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-038504","json":"https://secwatch.observer/filing/0001628280-26-038504.json","markdown":"https://secwatch.observer/filing/0001628280-26-038504.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1530979/000162828026038504/0001628280-26-038504-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1530979/000162828026038504/hnst-20260520.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 25, 2026, Saira Ramasastry, M.S., M.Phil., a member of the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) and Chair of the Company’s Audit Committee (the Audit Committee), informed the Company that, due to a business conflict, she will be stepping down from her role as a member of the Board and the Audit Committee, effective May 26, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038630/0001628280-26-038630-index.htm","comparable_excerpt":"On May 20, 2026, the Board of Directors of The Honest Company, Inc. (the “Company”) approved the promotion of Curtiss Bruce to the position of Chief Financial & Operating Officer, effective May 21, 2026 (the “Effective Date”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1530979/000162828026038504/0001628280-26-038504-index.htm"}},{"accession":"0001193125-26-251709","ticker":"CRVL","company_name":"CORVEL CORP","filed_at":"2026-06-01T21:05:42+00:00","headline":"CorVel CEO Michael Combs to become Executive Chair; Sarah Scott appointed CEO and President effective July 1, 2026","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251709","json":"https://secwatch.observer/filing/0001193125-26-251709.json","markdown":"https://secwatch.observer/filing/0001193125-26-251709.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/874866/000119312526251709/0001193125-26-251709-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874866/000119312526251709/d24231d8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 25, 2026, Saira Ramasastry, M.S., M.Phil., a member of the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) and Chair of the Company’s Audit Committee (the Audit Committee), informed the Company that, due to a business conflict, she will be stepping down from her role as a member of the Board and the Audit Committee, effective May 26, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038630/0001628280-26-038630-index.htm","comparable_excerpt":"In connection with the leadership transition, the Board appointed Sarah Scott to serve as Chief Executive Officer and President of the Company, effective July 1, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/874866/000119312526251709/0001193125-26-251709-index.htm"}},{"accession":"0001140361-26-023584","ticker":"WTTR","company_name":"Select Water Solutions, Inc.","filed_at":"2026-06-01T21:00:50+00:00","headline":"Select Water Solutions COO Skarke moves to Chief Commercial Officer; no successor named","event_type":"leadership","sec_items":["5.02","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-023584","json":"https://secwatch.observer/filing/0001140361-26-023584.json","markdown":"https://secwatch.observer/filing/0001140361-26-023584.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1693256/000114036126023584/0001140361-26-023584-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1693256/000114036126023584/ef20075332_8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 25, 2026, Saira Ramasastry, M.S., M.Phil., a member of the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) and Chair of the Company’s Audit Committee (the Audit Committee), informed the Company that, due to a business conflict, she will be stepping down from her role as a member of the Board and the Audit Committee, effective May 26, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038630/0001628280-26-038630-index.htm","comparable_excerpt":"Effective June 1, 2026, Michael C. Skarke transitioned from serving as the Executive Vice President and Chief Operating Officer of Select Water Solutions, Inc. (the “Company”) to serving as the Company’s Executive Vice President and Chief Commercial Officer,","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1693256/000114036126023584/0001140361-26-023584-index.htm"}},{"accession":"0001671933-26-000063","ticker":"TTD","company_name":"Trade Desk, Inc.","filed_at":"2026-06-01T20:35:28+00:00","headline":"The Trade Desk appoints Nate Olmstead as CFO effective July 9, 2026; interim CFO Davis resumes CAO role","event_type":"leadership","sec_items":["5.02","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001671933-26-000063","json":"https://secwatch.observer/filing/0001671933-26-000063.json","markdown":"https://secwatch.observer/filing/0001671933-26-000063.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671933/000167193326000063/0001671933-26-000063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671933/000167193326000063/ttd-20260601.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 25, 2026, Saira Ramasastry, M.S., M.Phil., a member of the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) and Chair of the Company’s Audit Committee (the Audit Committee), informed the Company that, due to a business conflict, she will be stepping down from her role as a member of the Board and the Audit Committee, effective May 26, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038630/0001628280-26-038630-index.htm","comparable_excerpt":"On June 1, 2026, The Trade Desk, Inc. (the “Company”) announced the appointment of Nate Olmstead, age 54, as the Company’s chief financial officer.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1671933/000167193326000063/0001671933-26-000063-index.htm"}},{"accession":"0000105770-26-000080","ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2026-06-01T20:32:30+00:00","headline":"West Pharmaceutical appoints Michel Lagarde as CEO; Green retires, Friel becomes Chair","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000105770-26-000080","json":"https://secwatch.observer/filing/0000105770-26-000080.json","markdown":"https://secwatch.observer/filing/0000105770-26-000080.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000080/0000105770-26-000080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000080/wst-20260531.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 25, 2026, Saira Ramasastry, M.S., M.Phil., a member of the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) and Chair of the Company’s Audit Committee (the Audit Committee), informed the Company that, due to a business conflict, she will be stepping down from her role as a member of the Board and the Audit Committee, effective May 26, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038630/0001628280-26-038630-index.htm","comparable_excerpt":"As of the Start Date, Mr. Green will resign as a member of the Board and Mr. Lagarde will be appointed as a member of the Board to fill that vacancy.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000080/0000105770-26-000080-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}